High-resolution mass spectrometry in toxicology: current status and future perspectives
暂无分享,去创建一个
[1] M. Meyer,et al. Contribution of human esterases to the metabolism of selected drugs of abuse. , 2015, Toxicology letters.
[2] M. Thevis,et al. Annual banned-substance review: analytical approaches in human sports drug testing. , 2012, Drug testing and analysis.
[3] M. Meyer,et al. Toxicokinetics of new psychoactive substances: plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212-2 studied using in vitro tools and LC-HR-MS/MS. , 2016, Drug testing and analysis.
[4] J. Znaleziona,et al. Determination and identification of synthetic cannabinoids and their metabolites in different matrices by modern analytical techniques - a review. , 2015, Analytica chimica acta.
[5] Frederick G. Strathmann,et al. A hybrid approach to urine drug testing using high-resolution mass spectrometry and select immunoassays. , 2015, American journal of clinical pathology.
[6] M. Huestis,et al. Metabolic profiling of new synthetic cannabinoids AMB and 5F-AMB by human hepatocyte and liver microsome incubations and high-resolution mass spectrometry. , 2016, Rapid communications in mass spectrometry : RCM.
[7] M. Meyer,et al. Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse. , 2014, Toxicology letters.
[8] S. Johansen,et al. Screening for illicit and medicinal drugs in whole blood using fully automated SPE and ultra-high-performance liquid chromatography with TOF-MS with data-independent acquisition. , 2013, Journal of separation science.
[9] Ruedi Aebersold,et al. Using data‐independent, high‐resolution mass spectrometry in protein biomarker research: Perspectives and clinical applications , 2015, Proteomics. Clinical applications.
[10] Folker Westphal,et al. The in vivo and in vitro metabolism and the detectability in urine of 3',4'-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenone-type designer drug, studied by GC-MS and LC-MS(n.). , 2014, Drug testing and analysis.
[11] Markus R Meyer,et al. Multiple stage MS in analysis of plasma, serum, urine and in vitro samples relevant to clinical and forensic toxicology. , 2016, Bioanalysis.
[12] H. Maurer. Demands on scientific studies in clinical toxicology. , 2007, Forensic science international.
[13] B. Shen,et al. Rapid screening of drugs of abuse in human urine by high-performance liquid chromatography coupled with high resolution and high mass accuracy hybrid linear ion trap-Orbitrap mass spectrometry. , 2013, Journal of chromatography. A.
[14] Bruno Domon,et al. Advances in high‐resolution accurate mass spectrometry application to targeted proteomics , 2015, Proteomics.
[15] M. Meyer,et al. In vitro approaches to studying the metabolism of new psychoactive compounds. , 2011, Drug testing and analysis.
[16] Emma K. Farrell,et al. Biosynthesis, degradation and pharmacological importance of the fatty acid amides. , 2008, Drug discovery today.
[17] H. Neels,et al. Advances in detection of antipsychotics in biological matrices. , 2015, Clinica chimica acta; international journal of clinical chemistry.
[18] I. Zamora,et al. Software-aided cytochrome P450 reaction phenotyping and kinetic analysis in early drug discovery. , 2016, Rapid communications in mass spectrometry : RCM.
[19] C. J. Schmitt,et al. Validated electrospray liquid chromatographic–mass spectrometric assay for the determination of the mushroom toxins α- and β-amanitin in urine after immunoaffinity extraction , 2000 .
[20] Kayla N. Ellefsen,et al. 4-Methoxy-α-PVP: in silico prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry , 2015, Forensic Toxicology.
[21] M. Yarmush,et al. Emerging In Vitro Liver Technologies for Drug Metabolism and Inter-Organ Interactions. , 2016, Tissue engineering. Part B, Reviews.
[22] Wilhelm Schänzer,et al. Annual banned-substance review: analytical approaches in human sports drug testing. , 2010, Drug testing and analysis.
[23] M. Meyer,et al. Biotransformation and detectability of the designer drug 2,5-dimethoxy-4-propylphenethylamine (2C-P) studied in urine by GC-MS, LC-MSn, and LC-high-resolution-MSn , 2014, Analytical and Bioanalytical Chemistry.
[24] M. Meyer,et al. Direct analysis of the mushroom poisons α- and β-amanitin in human urine using a novel on-line turbulent flow chromatography mode coupled to liquid chromatography-high resolution-mass spectrometry/mass spectrometry. , 2014, Journal of chromatography. A.
[25] Herbert Oberacher,et al. Applying ‘Sequential Windowed Acquisition of All Theoretical Fragment Ion Mass Spectra’ (SWATH) for systematic toxicological analysis with liquid chromatography-high-resolution tandem mass spectrometry , 2014, Analytical and Bioanalytical Chemistry.
[26] G. Lawson,et al. Bisoprolol, ramipril and simvastatin determination in dried blood spot samples using LC-HRMS for assessing medication adherence. , 2013, Journal of pharmaceutical and biomedical analysis.
[27] C. Kuo,et al. Screening and confirmation of 62 drugs of abuse and metabolites in urine by ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry. , 2013, Journal of analytical toxicology.
[28] Mingshe Zhu,et al. Applications of mass spectrometry in drug metabolism: 50 years of progress* , 2015, Drug metabolism reviews.
[29] C. Erratico,et al. Liquid chromatography-quadrupole time-of-flight mass spectrometry for screening in vitro drug metabolites in humans: investigation on seven phenethylamine-based designer drugs. , 2015, Journal of pharmaceutical and biomedical analysis.
[30] M. Castaneto,et al. Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices , 2015, Drug metabolism reviews.
[31] M. Huestis,et al. Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry , 2014, Analytical and Bioanalytical Chemistry.
[32] M. Meyer,et al. Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-HR-MS/MS. , 2014, Drug testing and analysis.
[33] M. Meyer,et al. Studies on the metabolism and toxicological detection of glaucine, an isoquinoline alkaloid from Glaucium flavum (Papaveraceae), in rat urine using GC-MS, LC-MS(n) and LC-high-resolution MS(n). , 2013, Journal of mass spectrometry : JMS.
[34] Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-Contribution of human cytochrome P450 isozymes to their main phase I metabolic steps. , 2015, Toxicology letters.
[35] V. Gökmen,et al. Future perspectives in Orbitrap™-high-resolution mass spectrometry in food analysis: a review , 2015, Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment.
[36] Kurt R. Lehner,et al. Linear pharmacokinetics of 3,4‐methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects , 2016, Addiction biology.
[37] Nandkishor S. Chindarkar,et al. Liquid chromatography high-resolution TOF analysis: investigation of MSE for broad-spectrum drug screening. , 2014, Clinical chemistry.
[38] Shuguang Ma,et al. Data acquisition and data mining techniques for metabolite identification using LC coupled to high-resolution MS. , 2013, Bioanalysis.
[39] M. Huestis,et al. High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human Hepatocytes. , 2016, Clinical chemistry.
[40] T. Croley,et al. Non-targeted screening approaches for contaminants and adulterants in food using liquid chromatography hyphenated to high resolution mass spectrometry. , 2016, Journal of chromatography. A.
[41] M. Meyer,et al. Dimethocaine, a synthetic cocaine derivative: studies on its in vitro metabolism catalyzed by P450s and NAT2. , 2014, Toxicology letters.
[42] Mingshe Zhu,et al. Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA , 2015, The AAPS Journal.
[43] Frank T Peters,et al. Studies on the metabolism and toxicological detection of the designer drug 4-methylthioamphetamine (4-MTA) in human urine using gas chromatography-mass spectrometry. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[44] H. Maurer,et al. Identification of human cytochrome P450 2D6 as major enzyme involved in the O-demethylation of the designer drug p-methoxymethamphetamine. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[45] M. Kettner,et al. Metabolic patterns of JWH-210, RCS-4, and THC in pig urine elucidated using LC-HR-MS/MS: Do they reflect patterns in humans? , 2017, Drug testing and analysis.
[46] M. Meyer,et al. 2-Methiopropamine, a thiophene analogue of methamphetamine: studies on its metabolism and detectability in the rat and human using GC-MS and LC-(HR)-MS techniques , 2013, Analytical and Bioanalytical Chemistry.
[47] A. Wu,et al. Comparison of Information-Dependent Acquisition on a Tandem Quadrupole TOF vs a Triple Quadrupole Linear Ion Trap Mass Spectrometer for Broad-Spectrum Drug Screening. , 2016, Clinical chemistry.
[48] L. Couchman,et al. Measurement of the Direct Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Plasma Using Turbulent Flow Liquid Chromatography With High-Resolution Mass Spectrometry , 2014, Therapeutic drug monitoring.
[49] M. Huestis,et al. Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urine. , 2011, Journal of mass spectrometry : JMS.
[50] M. Meyer,et al. In vitro cytochrome P450 inhibition potential of methylenedioxy-derived designer drugs studied with a two-cocktail approach , 2016, Archives of Toxicology.
[51] Kayla N. Ellefsen,et al. In vitro, in vivo and in silico metabolic profiling of α-pyrrolidinopentiothiophenone, a novel thiophene stimulant. , 2016, Bioanalysis.
[52] M. Burnier,et al. Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis , 2015, Clinical Research in Cardiology.
[53] M. Meyer,et al. Production of human phase 1 and 2 metabolites by whole-cell biotransformation with recombinant microbes. , 2010, Bioanalysis.
[54] Kayla N. Ellefsen,et al. Simultaneous quantification of 28 synthetic cathinones and metabolites in urine by liquid chromatography-high resolution mass spectrometry , 2013, Analytical and Bioanalytical Chemistry.
[55] H. Maurer,et al. New designer drug p-methoxymethamphetamine: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[56] Mingshe Zhu,et al. First Characterization of AKB-48 Metabolism, a Novel Synthetic Cannabinoid, Using Human Hepatocytes and High-Resolution Mass Spectrometry , 2013, The AAPS Journal.
[57] M. Meyer,et al. Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn , 2013, Analytical and Bioanalytical Chemistry.
[58] Adrian Covaci,et al. A data-independent acquisition workflow for qualitative screening of new psychoactive substances in biological samples , 2015, Analytical and Bioanalytical Chemistry.
[59] M. Ericsson,et al. Methods for urine drug testing using one-step dilution and direct injection in combination with LC-MS/MS and LC-HRMS. , 2014, Bioanalysis.
[60] M. Meyer. New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics , 2016, Archives of Toxicology.
[61] S. Toennes,et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis , 2013, Journal of hypertension.
[62] M. Meyer,et al. Toxicokinetics of novel psychoactive substances: characterization of N-acetyltransferase (NAT) isoenzymes involved in the phase II metabolism of 2C designer drugs. , 2014, Toxicology letters.
[63] M. Meyer,et al. Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. , 2016, Toxicology letters.
[64] GC-MS and LC-(high-resolution)-MSn studies on the metabolic fate and detectability of camfetamine in rat urine , 2014, Analytical and Bioanalytical Chemistry.
[65] M. Meyer,et al. Current position of high-resolution MS for drug quantification in clinical & forensic toxicology. , 2014, Bioanalysis.
[66] Mingshe Zhu,et al. Metabolite profiling of RCS-4, a novel synthetic cannabinoid designer drug, using human hepatocyte metabolism and TOF-MS. , 2014, Bioanalysis.
[67] Robert Kronstrand,et al. In Vitro and In Vivo Human Metabolism of Synthetic Cannabinoids FDU-PB-22 and FUB-PB-22 , 2016, The AAPS Journal.
[68] M. Meyer,et al. Studies on the metabolism and detectability of the designer drug β-naphyrone in rat urine using GC-MS and LC-HR-MS/MS. , 2013, Drug testing and analysis.
[69] S. Fu,et al. Analysis of new designer drugs in post-mortem blood using high-resolution mass spectrometry. , 2015, Journal of analytical toxicology.
[70] M. Meyer,et al. Metabolic fate of desomorphine elucidated using rat urine, pooled human liver preparations, and human hepatocyte cultures as well as its detectability using standard urine screening approaches , 2016, Analytical and Bioanalytical Chemistry.
[71] Marten Hanura,et al. UPAYA UNITED NATIONS OFFICE ON DRUGS AND CRIME (UNODC) DALAM MENANGANI DRUG TRAFFICKING DI AFGHANISTAN PERIODE 2012-2013 , 2015 .
[72] Hassan Khan,et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. , 2013, European heart journal.
[73] C. Junot,et al. Multiplex quantification of protein toxins in human biofluids and food matrices using immunoextraction and high-resolution targeted mass spectrometry. , 2015, Analytical chemistry.
[74] Odd Hordvin,et al. The Drug Situation in Norway 2011 : Annual report to the European Monitoring Centre for Drugs and Drug Addiction - EMCDDA , 2009 .
[75] M. Thevis,et al. Human sports drug testing by mass spectrometry. , 2017, Mass spectrometry reviews.
[76] Myron S. Cohen,et al. The development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human blood. , 2014, Clinica chimica acta; international journal of clinical chemistry.
[77] Thomas Kraemer,et al. Liquid chromatography, in combination with a quadrupole time-of-flight instrument (LC QTOF), with sequential window acquisition of all theoretical fragment-ion spectra (SWATH) acquisition: systematic studies on its use for screenings in clinical and forensic toxicology and comparison with informatio , 2014, Analytical chemistry.
[78] M. Meyer,et al. Studies on the in vivo contribution of human cytochrome P450s to the hepatic metabolism of glaucine, a new drug of abuse. , 2013, Biochemical pharmacology.
[79] R. Gerona,et al. Non-targeted screening for novel psychoactive substances among agitated emergency department patients , 2016, Clinical toxicology.
[80] Ilkka Ojanperä,et al. A high-sensitivity ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry (UHPLC-HR-TOFMS) method for screening synthetic cannabinoids and other drugs of abuse in urine , 2013, Analytical and Bioanalytical Chemistry.
[81] P. Thai,et al. Critical review on the stability of illicit drugs in sewers and wastewater samples. , 2016, Water research.
[82] A. Eschalier,et al. Fully automated semi-quantitative toxicological screening in three biological matrices using turbulent flow chromatography/high resolution mass spectrometry. , 2016, Clinica chimica acta; international journal of clinical chemistry.
[83] Mingshe Zhu,et al. Metabolic characterization of AH-7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation. , 2016, Drug testing and analysis.
[84] Studies on the metabolism and the detectability of 4-methyl-amphetamine and its isomers 2-methyl-amphetamine and 3-methyl-amphetamine in rat urine using GC-MS and LC-(high-resolution)-MSn , 2014, Analytical and Bioanalytical Chemistry.
[85] H. Maurer,et al. Diphenidine, a new psychoactive substance: metabolic fate elucidated with rat urine and human liver preparations and detectability in urine using GC-MS, LC-MSn , and LC-HR-MSn. , 2016, Drug testing and analysis.
[86] S. Ferrara,et al. Monitoring Haloperidol Exposure in Body Fluids and Hair of Children by Liquid Chromatography–High-Resolution Mass Spectrometry , 2013, Therapeutic drug monitoring.
[87] Marilyn A Huestis,et al. First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. , 2013, Clinical chemistry.
[88] K. Johnson-Davis,et al. Comparison of drug detection by three quadrupole time-of-flight mass spectrometry platforms. , 2015, Journal of analytical toxicology.
[89] J. Tomková,et al. Simultaneous determination of mushroom toxins α-amanitin, β-amanitin and muscarine in human urine by solid-phase extraction and ultra-high-performance liquid chromatography coupled with ultra-high-resolution TOF mass spectrometry. , 2015, Forensic science international.
[90] R. Kronstrand,et al. LC-QTOF-MS as a superior strategy to immunoassay for the comprehensive analysis of synthetic cannabinoids in urine , 2014, Analytical and Bioanalytical Chemistry.
[91] M. Meyer,et al. Dimethocaine, a synthetic cocaine analogue: studies on its in-vivo metabolism and its detectability in urine by means of a rat model and liquid chromatography–linear ion-trap (high-resolution) mass spectrometry , 2014, Analytical and Bioanalytical Chemistry.
[92] D. Boels,et al. Elucidation of the metabolites of the novel psychoactive substance 4-methyl-N-ethyl-cathinone (4-MEC) in human urine and pooled liver microsomes by GC-MS and LC-HR-MS/MS techniques and of its detectability by GC-MS or LC-MS(n) standard screening approaches. , 2015, Drug testing and analysis.
[93] M. Meyer,et al. Low resolution and high resolution MS for studies on the metabolism and toxicological detection of the new psychoactive substance methoxypiperamide (MeOP). , 2015, Journal of mass spectrometry : JMS.
[94] L. Fanton,et al. A validated method for quantifying atractyloside and carboxyatractyloside in blood by HPLC-HRMS/MS, a non-fatal case of intoxication with Atractylis gummifera L. , 2014, Journal of analytical toxicology.
[95] M. Meyer,et al. Studies on the metabolism and detectability of the emerging drug of abuse diphenyl-2-pyrrolidinemethanol (D2PM) in rat urine using GC-MS and LC-HR-MS/MS. , 2013, Journal of mass spectrometry : JMS.
[96] Anna T. Kelly,et al. Validation of LC-TOF-MS screening for drugs, metabolites, and collateral compounds in forensic toxicology specimens. , 2013, Journal of analytical toxicology.
[97] A. DeCaprio,et al. Covalent thiol adducts arising from reactive intermediates of cocaine biotransformation. , 2013, Chemical research in toxicology.
[98] M. Meyer,et al. Orbitrap technology for comprehensive metabolite-based liquid chromatographic-high resolution-tandem mass spectrometric urine drug screening - exemplified for cardiovascular drugs. , 2015, Analytica chimica acta.
[99] I. Morel,et al. Amatoxins (α- and β-Amanitin) and phallotoxin (Phalloidin) analyses in urines using high-resolution accurate mass LC-MS technology. , 2014, Journal of analytical toxicology.
[100] H. Maurer,et al. Lefetamine, a controlled drug and pharmaceutical lead of new designer drugs: synthesis, metabolism, and detectability in urine and human liver preparations using GC-MS, LC-MSn, and LC-high resolution-MS/MS , 2015, Analytical and Bioanalytical Chemistry.
[101] Mingshe Zhu,et al. High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes. , 2015, Drug testing and analysis.
[102] H. Maurer,et al. New Psychoactive Substances: Chemistry, Pharmacology, Metabolism, and Detectability of Amphetamine Derivatives With Modified Ring Systems , 2016, Therapeutic drug monitoring.
[103] M. Meyer,et al. Current status of hyphenated mass spectrometry in studies of the metabolism of drugs of abuse, including doping agents , 2011, Analytical and Bioanalytical Chemistry.
[104] F. Peters,et al. Biotechnological synthesis of the designer drug metabolite 4'-hydroxymethyl-alpha-pyrrolidinohexanophenone in fission yeast heterologously expressing human cytochrome P450 2D6--a versatile alternative to multistep chemical synthesis. , 2009, Journal of analytical toxicology.
[105] Irene van den Broek,et al. Current trends in mass spectrometry of peptides and proteins: Application to veterinary and sports-doping control. , 2015, Mass spectrometry reviews.
[106] M. Meyer,et al. Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC–MS, LC–MSn, and LC–HR–MS–MS , 2015, Analytical and Bioanalytical Chemistry.
[107] H. Nakayama,et al. High-resolution mass spectrometric determination of the synthetic cannabinoids MAM-2201, AM-2201, AM-2232, and their metabolites in postmortem plasma and urine by LC/Q-TOFMS , 2015, International Journal of Legal Medicine.
[108] F. Peters. Recent developments in urinalysis of metabolites of new psychoactive substances using LC-MS. , 2014, Bioanalysis.
[109] I. Dasgupta,et al. A Novel 'Dilute-and-Shoot' Liquid Chromatography-Tandem Mass Spectrometry Method for the Screening of Antihypertensive Drugs in Urine. , 2015, Journal of analytical toxicology.
[110] Mingshe Zhu,et al. Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS. , 2014, Bioanalysis.
[111] M. Uder,et al. Adherence to Antihypertensive Medication in Treatment‐Resistant Hypertension Undergoing Renal Denervation , 2016, Journal of the American Heart Association.
[112] M. Meyer,et al. Development and validation of a liquid-chromatography high-resolution tandem mass spectrometry approach for quantification of nine cytochrome P450 (CYP) model substrate metabolites in an in vitro CYP inhibition cocktail , 2014, Analytical and Bioanalytical Chemistry.
[113] K. Linnet,et al. Screening of 30 acidic and neutral pharmaceuticals in whole blood by fully automated SPE and UPLC-TOF-MS(E.). , 2013, Drug testing and analysis.
[114] Marilyn A Huestis,et al. Simultaneous determination of 40 novel psychoactive stimulants in urine by liquid chromatography-high resolution mass spectrometry and library matching. , 2015, Journal of chromatography. A.
[115] M. Meyer,et al. Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MSn techniques , 2015, Analytical and Bioanalytical Chemistry.
[116] Markus R Meyer,et al. Review: LC coupled to low- and high-resolution mass spectrometry for new psychoactive substance screening in biological matrices - Where do we stand today? , 2016, Analytica chimica acta.
[117] H. Maurer. On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry. , 1996, Therapeutic drug monitoring.
[118] M. Meyer,et al. Studies on the microbial biotransformation of the novel psychoactive substance methylenedioxypyrovalerone (MDPV) in wastewater by means of liquid chromatography-high resolution mass spectrometry/mass spectrometry. , 2014, The Science of the total environment.
[119] Marilyn A Huestis,et al. Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry , 2014, Analytical and Bioanalytical Chemistry.
[120] M. Meyer,et al. Metabolic fate, mass spectral fragmentation, detectability, and differentiation in urine of the benzofuran designer drugs 6-APB and 6-MAPB in comparison to their 5-isomers using GC-MS and LC-(HR)-MSn techniques , 2015, Analytical and Bioanalytical Chemistry.
[121] Thomas Kraemer,et al. Liquid chromatography, in combination with a quadrupole time-of-flight instrument, with sequential window acquisition of all theoretical fragment-ion spectra acquisition: validated quantification of 39 antidepressants in whole blood as part of a simultaneous screening and quantification procedure. , 2015, Analytical chemistry.
[122] Adam S. Hayward,et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME , 2013, Archives of Toxicology.
[123] M. Meyer,et al. Current applications of high-resolution mass spectrometry in drug metabolism studies , 2012, Analytical and Bioanalytical Chemistry.
[124] H. Maurer,et al. Qualitative metabolism assessment and toxicological detection of xylazine, a veterinary tranquilizer and drug of abuse, in rat and human urine using GC–MS, LC–MSn, and LC–HR-MSn , 2013, Analytical and Bioanalytical Chemistry.
[125] T. Tuzimski,et al. Recent Trends in Sample Preparation and Liquid Chromatography/Mass Spectrometry for Pesticide Residue Analysis in Food and Related Matrixes. , 2015, Journal of AOAC International.
[126] A. Pelander,et al. Simultaneous identification and quantification of new psychoactive substances in blood by GC-APCI-QTOFMS coupled to nitrogen chemiluminescence detection without authentic reference standards , 2016, Analytical and Bioanalytical Chemistry.
[127] Damià Barceló,et al. Advances in liquid chromatography–high-resolution mass spectrometry for quantitative and qualitative environmental analysis , 2015, Analytical and Bioanalytical Chemistry.
[128] M. Böhm,et al. Witnessed drug intake before planned denervation--always harmless? , 2015, International journal of cardiology.
[129] M. Meyer,et al. Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MSn, and LC-HR-MS/MS , 2015, Analytical and Bioanalytical Chemistry.